Bing–Neel syndrome
| Bing–Neel syndrome | |
|---|---|
| Synonyms | |
| Pronounce | N/A |
| Specialty | N/A |
| Symptoms | Headache, Confusion, Seizures, Cranial nerve palsies, Ataxia, Cognitive impairment |
| Complications | |
| Onset | |
| Duration | |
| Types | |
| Causes | Waldenström's macroglobulinemia |
| Risks | |
| Diagnosis | MRI, CSF analysis, Biopsy |
| Differential diagnosis | Central nervous system lymphoma, Multiple sclerosis, Infectious meningitis |
| Prevention | N/A |
| Treatment | Chemotherapy, Intrathecal therapy, Radiation therapy |
| Medication | Rituximab, Ibrutinib, Methotrexate |
| Prognosis | |
| Frequency | Rare |
| Deaths | |
Bing–Neel syndrome is a rare and aggressive type of lymphoma that affects the central nervous system. It is associated with Waldenström's macroglobulinemia, a type of non-Hodgkin lymphoma.
Symptoms[edit]
The symptoms of Bing–Neel syndrome can vary widely, but often include neurological problems such as headache, dizziness, confusion, and vision problems. Other symptoms can include fatigue, weight loss, and night sweats.
Diagnosis[edit]
Diagnosis of Bing–Neel syndrome can be challenging due to its rarity and the nonspecific nature of its symptoms. It is often diagnosed through a combination of blood tests, imaging studies, and biopsy of the affected tissue.
Treatment[edit]
Treatment for Bing–Neel syndrome typically involves chemotherapy, radiation therapy, and sometimes stem cell transplantation. The choice of treatment depends on the patient's overall health, the extent of the disease, and the patient's personal preferences.
Prognosis[edit]
The prognosis for Bing–Neel syndrome is generally poor, with a median survival time of less than two years. However, some patients may live longer with aggressive treatment.
See also[edit]
References[edit]